Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2012 by Grupo Hospital de Madrid.
Recruitment status was  Recruiting
Sponsor:
Information provided by (Responsible Party):
Sofia Perea, Director Clinical Trials Unit., Grupo Hospital de Madrid
ClinicalTrials.gov Identifier:
NCT01394120
First received: July 5, 2011
Last updated: March 24, 2012
Last verified: March 2012

July 5, 2011
March 24, 2012
August 2011
December 2012   (final data collection date for primary outcome measure)
Overall Survival [ Time Frame: 1 year ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01394120 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer
Phase II Study of Chemotherapy Selection Based on Therapeutic Targets for the Treatment of Advanced Pancreatic Cancer

In recent years, treatment of advanced pancreatic cancer is changing. Currently, there are several active schedules of chemotherapy that can be used, such as gemcitabine as monotherapy or in combination with capecitabine or erlotinib, and FOLFIRINOX. Moreover, the development of biomarker (therapeutic targets) that can predicte response to treatment is a new important tool to be used in clinical practice to select the best scheme for each patient. Preliminary studies showed that therapeutic target determination, using tumor tissue collected from patients, could determine the presence of groups of "chemotherapy responders". Such is the case of EGFR amplification and/or K-Ras gene status and correlation with response to erlotinib. Moreover, Thymidilate Synthase, Thimidine Phosphorylase, ERCC-1 and Topoisomerase I expression by immunohistochemistry in GI tumor samples has been related to resistance or response to 5FU-capecitabine, oxaliplatin and irinotecan respectively. Based on this data the investigators designed a phase II clinical trial to evaluate the efficacy of selected treatment for pancreatic cancer patients based on the determination of therapeutic targets. The therapeutic target-driven treatment efficacy will be compared to the prospective treatment of a control group of patients treated at the discretion of the physician-researcher

Study Phase: Phase 2 Trial

Study Objetives:

  • Primary end-point. Proportion of patients alive after 12 months in patients with advanced pancreatic carcinoma individually selected and grouped according to the expression in tumor tissue for therapeutic targets.
  • Secondary end-points. 1. Assessing the feasibility of the method of patient-treatment-selection based on tumor tissue expression of therapeutic targets. 2. Overal survival comparison between Gemcitabine single agent treatment and the rest of chemotherapy schedules. 3. Determination of progression-free survival for each treatment group. 4. Determination of toxicity in all the patients.

Study population and Number of subject: A total of 60 pancreatic cancer patients with advanced pancreas cancer with no previous systemic treatment are expected to be enrolled.

Study design and schedule. Patients will be randomized (1:1) to a control arm or an experimental treatment arm guided by therapeutic targets. In the control arm, patients are treated with conventional chemotherapy regimens at the discretion of the investigator. In the experimental arm, patients are treated as determined in tumor tissue available for biomarker TS, TP, ERCC-1, Topo-1, K-Ras mutation and EGFR FISH, choosing FOLFIRINOX schemas, FOLFOX, FOLFIRI, Gemcitabine-Capecitabine Gemcitabine-Erlotinib, Gemcitabine single agent. All patients will be analyzed by intention to treat

Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Carcinoma, Pancreatic Ductal
  • Drug: Targeted Therapy Tailored Treatment

    Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen

    • Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX
    • TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX
    • TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI
    • TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine
    • TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent
    • TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib
    Other Name: Individualized treatment selection based on predictors of response biomarkers
  • Drug: Standard Chemotherapy
    Patients treated based on investigator´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent
    Other Name: Treatment at the investigator's discretion
  • Experimental: Tarteted Therapy
    Intervention: Drug: Targeted Therapy Tailored Treatment
  • Active Comparator: Standard Chemotherapy
    Intervention: Drug: Standard Chemotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
December 2013
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologic diagnosis of pancreas adenocarcinoma
  • Clinical stage IV
  • Feasible patient for chemotherapy
  • Availability of tumor tissue or possibility of a tumor biopsy to define therapeutic targets
  • Informed written consent

Exclusion Criteria:

  • Previous systemic treatment for advanced pancreas adenocarcinoma
  • Contraindication to the administration of any of the drugs used in the study: capecitabine, 5Fluouracil, irinotecan, oxaliplatin, gemcitabine or erlotinib
Both
18 Years and older
No
Spain
 
NCT01394120
TARGTHPANC 001, 2011-001017-13
Yes
Sofia Perea, Director Clinical Trials Unit., Grupo Hospital de Madrid
Sofia Perea, Director Clinical Trials Unit.
Not Provided
Principal Investigator: Manuel Hidalgo, MD
Grupo Hospital de Madrid
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP